Michael Hutchinson

Further evidence of dementia in SPG4-linked autosomal dominant hereditary spastic paraplegia.

Cervical dystonia following peripheral trauma--a case-control study.

Familial adolescent-onset scoliosis and later segmental dystonia in an Irish family.

Inherited myoclonus-dystonia and epilepsy: further evidence of an association?

Population frequency of HLA haplotypes contributes to the prevalence difference of multiple sclerosis in Ireland.

The patient knows best: significant change in the physical component of the Multiple Sclerosis Impact Scale (MSIS-29 physical).

Outcome of beta-interferon treatment in relapsing-remitting multiple sclerosis: a Bayesian analysis.

Sporadic adult onset dystonia: sensory abnormalities as an endophenotype in unaffected relatives.

Molding the sensory cortex: spatial acuity improves after botulinum toxin treatment for cervical dystonia.

REEP1 mutation spectrum and genotype/phenotype correlation in hereditary spastic paraplegia type 31.

Natalizumab: A new treatment for relapsing remitting multiple sclerosis.

Identification of the SPG15 gene, encoding spastizin, as a frequent cause of complicated autosomal-recessive spastic paraplegia, including Kjellin syndrome.

The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL.

Striatal morphology correlates with sensory abnormalities in unaffected relatives of cervical dystonia patients.

Predicting and preventing the future: actively managing multiple sclerosis.

Phenotypic diversity associated with the mitochondrial m.8313G>A point mutation.

Reactivation of BK polyomavirus in patients with multiple sclerosis receiving natalizumab therapy.

Sensory ataxic neuropathy dysarthria and ophthalmoparesis (SANDO) in a sibling pair with a homozygous p.A467T POLG mutation.

Comparing endophenotypes in adult-onset primary torsion dystonia.

Discontinuing disease-modifying therapy in progressive multiple sclerosis: can we stop what we have started?

Clinically isolated syndrome: a protected zone for trials of new therapies?

Natalizumab therapy of multiple sclerosis.

Sporadic adult onset primary torsion dystonia is a genetic disorder by the temporal discrimination test.

Using atypical symptoms and red flags to identify non-demyelinating disease.

Translation initiator EIF4G1 mutations in familial Parkinson disease.

Controversies in multiple sclerosis: a series of debates.

The major cause of multiple sclerosis is environmental: genetics has a minor role--commentary.

Relapses do not matter in relation to long-term disability: commentary.

Truly benign multiple sclerosis is rare: let's stop fooling ourselves--commentary.

In assessing multiple sclerosis disease activity patient report measures are a waste of time: cut to the MRI scan!--Commentary.

Do not treat from CIS onset: evaluate disease course and prognosis first--commentary.

The neurologist's dilemma: MS is a grey matter disease that standard clinical and MRI measures cannot assess adequately--commentary.

We are about to cure MS in the next 10 years, even though we do not know its cause: commentary.

There is no such thing as a mild MS relapse. The mild relapse is an Anglo-Saxon delusion - commentary.

Deaths and disability from natalizumab are no longer tolerable: Commentary.

Industrial pharmaceutical drug research has done more for the health of people with MS than academic neurologists: commentary.

Rehabilitation therapy in MS: a short-term, expensive, placebo: commentary.

Only low frequency event-related EEG activity is compromised in multiple sclerosis: insights from an independent component clustering analysis.

Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study.

Treat patients with radiologically isolated syndrome when the MRI brain scan shows dissemination in time: commentary.

The only way to manage neurodegeneration in MS is to prevent it with effective anti-inflammatory therapy: commentary.

If I had CIS with MRI diagnostic of MS, I would take vitamin D 10,000 IU daily: Commentary.

The best clinical paper on multiple sclerosis in 2012: commentary.

CSF oligoclonal bands are important in the diagnosis of multiple sclerosis, unreasonably downplayed by the McDonald criteria 2010: Commentary.

Funding CCSVI research is/was a waste of valuable time, money and intellectual energy: commentary.

Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: subgroup analyses of the CONFIRM study.

Dose-related effects of vitamin D on immune responses in patients with clinically isolated syndrome and healthy control participants: study protocol for an exploratory randomized double- blind placebo-controlled trial.

The endophenotype and the phenotype: temporal discrimination and adult-onset dystonia.

One can prevent post-partum MS relapses by exclusive breast feeding: commentary.

Efficacy and safety of BG-12 (dimethyl fumarate) and other disease-modifying therapies for the treatment of relapsing-remitting multiple sclerosis: a systematic review and mixed treatment comparison.

Epstein-Barr virus is a necessary causative agent in the pathogenesis of multiple sclerosis: commentary.

Dexterity training improves manual precision in patients affected by essential tremor.

Evoked potentials are of little use in the diagnosis or monitoring of MS: commentary.

Temporal discrimination, a cervical dystonia endophenotype: penetrance and functional correlates.

MRI measures should be a primary outcome endpoint in phase III randomised controlled trials in multiple sclerosis: commentary.

Cervical dystonia: a disorder of the midbrain network for covert attentional orienting.

An evaluation of the role of environmental factors in the disease penetrance of cervical dystonia.

Epidemiology of Wilson's disease in Ireland.

A headset method for measuring the visual temporal discrimination threshold in cervical dystonia.

Optical coherence tomography should be part of the routine monitoring of patients with multiple sclerosis: commentary.

Spinal cord MRI should always be performed in clinically isolated syndrome patients: Commentary.

Multiparity in women with multiple sclerosis causes less long-term disability: commentary.

The best basic science paper in multiple sclerosis in 2013: Disease specific molecular events in cortical multiple sclerosis lesions.

We can compare the relative efficacy multiple sclerosis medications by examining the results of independent clinical trials: commentary.

Any evident MRI T2 lesion activity should guide change of therapy in multiple sclerosis--commentary.

Effects of delayed-release dimethyl fumarate on MRI measures in the phase 3 CONFIRM study.

Efficacy of delayed-release dimethyl fumarate in relapsing-remitting multiple sclerosis: integrated analysis of the phase 3 trials.

Unmet needs of multiple sclerosis patients in the community.

Managing flushing and gastrointestinal events associated with delayed-release dimethyl fumarate: Experiences of an international panel.

Sun exposure is an environmental factor for the development of blepharospasm.

A Network Meta-Analysis of Efficacy and Evaluation of Safety of Subcutaneous Pegylated Interferon Beta-1a versus Other Injectable Therapies for the Treatment of Relapsing-Remitting Multiple Sclerosis.

Symptomatic therapy in multiple sclerosis: Big pharma should do more--commentary.

Young Women do it Better: Sexual Dimorphism in Temporal Discrimination.

The only certain measure of the effectiveness of multiple sclerosis therapy is cerebrospinal neurofilament level: Commentary.

Multiple sclerosis relapse phenotype is an important, neglected determinant of disease-outcome: Commentary.

Neurodegeneration in multiple sclerosis is a process separate from inflammation: No.

Neural correlates of abnormal sensory discrimination in laryngeal dystonia.

Age-Related Sexual Dimorphism in Temporal Discrimination and in Adult-Onset Dystonia Suggests GABAergic Mechanisms.

Delayed P100-Like Latencies in Multiple Sclerosis: A Preliminary Investigation Using Visual Evoked Spread Spectrum Analysis.

Modeling the course and outcomes of MS is statistical twaddle--Commentary.

Exploring the unknown: electrophysiological and behavioural measures of visuospatial learning.

A useful annual review of cognition in relapsing MS is beyond most neurologists - Commentary.

Long-term effects of delayed-release dimethyl fumarate in multiple sclerosis: Interim analysis of ENDORSE, a randomized extension study.

All relapsing multiple sclerosis patients should be managed at a specialist clinic - Commentary.

Integrated multidisciplinary clinics should be the gold standard in managing progressive MS - Commentary.

The best clinical paper of 2013: Commentary.

Future placebo-controlled trials of disease modifying therapy in relapsing multiple sclerosis would be unethical: Commentary.

Marta Elian: Obituary.

Obituary.

Menstrual cycle and the temporal discrimination threshold.

A comparison of stimulus presentation methods in temporal discrimination testing.

Immediate thrombocytopenia at time of alemtuzumab infusion for multiple sclerosis - Not always self-limiting, fully reversible or predictable.

Effects of vitamin D3 in clinically isolated syndrome and healthy control participants: A double-blind randomised controlled trial.

Practice does not make perfect: Temporal discrimination in musicians with and without dystonia.

Disrupted superior collicular activity may reveal cervical dystonia disease pathomechanisms.

The premotor syndrome of cervical dystonia: Disordered processing of salient environmental stimuli.

Temporal Discrimination: Mechanisms and Relevance to Adult-Onset Dystonia.